RWA WEALTH PARTNERS, LLC has opened a new $30.8M position in $MRNA, per a new SEC 13F filing. This disclosure reflects the funds' holdings for the 09-30-2026 report period. You can see the fund's full portfolio on Quiver Quantitative, and also track the largest institutional owners of $MRNA.
$MRNA Hedge Fund Activity
We have seen 599 institutional investors add shares of $MRNA stock to their portfolio, and 378 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 7,096,057 shares (+13.7%) to their portfolio in Q3 2026, for an estimated $1,366,487,696
- BAILLIE GIFFORD & CO removed 6,768,791 shares (-37.2%) from their portfolio in Q3 2026, for an estimated $1,303,466,082
- D. E. SHAW & CO., INC. removed 5,157,808 shares (-99.5%) from their portfolio in Q2 2026, for an estimated $361,201,294
- PRICE T ROWE ASSOCIATES INC /MD/ added 4,850,982 shares (+656.8%) to their portfolio in Q2 2026, for an estimated $339,714,269
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. removed 4,838,884 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $931,823,891
- ALYESKA INVESTMENT GROUP, L.P. removed 3,490,366 shares (-86.2%) from their portfolio in Q2 2026, for an estimated $244,430,330
- INVESCO LTD. removed 3,157,809 shares (-54.6%) from their portfolio in Q3 2026, for an estimated $608,099,279
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$MRNA Insider Trading Activity
$MRNA insiders have traded $MRNA stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $MRNA stock by insiders over the last 6 months:
- STEPHEN HOGE (President) has made 0 purchases and 8 sales selling 318,952 shares for an estimated $37,631,803.
- STEPHANE BANCEL (Chief Executive Officer) has made 0 purchases and 4 sales selling 499,246 shares for an estimated $28,715,011.
- JAMES M MOCK (Chief Financial Officer) has made 0 purchases and 2 sales selling 34,836 shares for an estimated $4,685,093.
- SHANNON THYME KLINGER (Chief Legal Officer) has made 0 purchases and 2 sales selling 6,942 shares for an estimated $659,316.
- NOUBAR AFEYAN sold 9,263 shares for an estimated $433,878
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$MRNA Congressional Stock Trading
Members of Congress have traded $MRNA stock 4 times in the past 6 months. Of those trades, 2 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $MRNA stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 10/20.
- REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 3 times. They made 1 purchase worth up to $15,000 on 08/19 and 2 sales worth up to $30,000 on 09/24, 08/19.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
$MRNA Analyst Ratings
Wall Street analysts have issued reports on $MRNA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 3 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 11/09/2026
- Citigroup issued a "Sell" rating on 09/30/2026
- Rothschild & Co issued a "Sell" rating on 09/03/2026
- Argus Research issued a "Buy" rating on 08/28/2026
- JP Morgan issued a "Underweight" rating on 08/21/2026
To track analyst ratings and price targets for $MRNA, check out Quiver Quantitative's $MRNA forecast page.
$MRNA Price Targets
Multiple analysts have issued price targets for $MRNA recently. We have seen 13 analysts offer price targets for $MRNA in the last 6 months, with a median target of $90.0.
Here are some recent targets:
- Salveen Richter from Goldman Sachs set a target price of $195.0 on 11/09/2026
- Edward Tenthoff from Piper Sandler set a target price of $305.0 on 11/09/2026
- Tyler Van Buren from TD Cowen set a target price of $90.0 on 10/21/2026
- Terence Flynn from Morgan Stanley set a target price of $95.0 on 10/07/2026
- Geoff Meacham from Citigroup set a target price of $80.0 on 09/30/2026
- Simon Baker from Rothschild & Co set a target price of $81.0 on 09/03/2026
- John Eade from Argus Research set a target price of $180.0 on 08/28/2026
Note that there may be inaccuracies in these estimates due to filing errors by the funds, parsing errors by us, or other anomalies.
Check out Quiver Quantitative's $MRNA ticker page for more data.
